Polymorphism in the Vesicular Monoamine Transporter 2 Gene Decreases the Risk of Parkinson’s Disease in Han Chinese Men

Xinglong Yang,1 Pingrong Xu,2 Quanzhen Zhao,1 Ran An,1 Hua Jia,1 Zhuolin Liu,3 and Yanming Xu1

1Department of Neurology, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, Sichuan 610041, China
2Department of Pharmacy, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, Sichuan 610041, China
3Department of Neurology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China

Correspondence should be addressed to Yanming Xu; neuroxym999@163.com

Received 30 April 2015; Revised 19 June 2015; Accepted 24 June 2015

Background. Polymorphisms rs363371 and rs363324 in the vesicular monoamine transporter 2 (VMAT2) gene have been associated with risk of PD in an Italian population, and our aim is to investigate the association between the two single-nucleotide polymorphisms and PD in Han Chinese. Methods. 561 Han Chinese PD patients and 491 healthy age- and gender-matched controls were genotyped using Ligase detection reaction (LDR) method. Result. Both of patient and control groupsshowedsimilargenotypefrequencies between patients and controls at both rs363371 and rs363324, as well as similarminorallele frequencies at rs363371 (P = 0.452) and rs363324 (P = 0.413). None of the observed haplotypes showed a significant association with PD. Subgroup analysis by gender and age at onset revealed a significant association between the A allele of rs363371 in Han Chinese males relative to healthy controls (OR 0.799, 95% CI 0.665 to 0.959, P = 0.016), and this association remained significant after adjusting for age (OR 0.785, 95% CI 0.652 to 0.945, P = 0.011). Conclusion. These results suggest that polymorphism of VMAT2 locus is associated with risk of PD in Han Chinese overall but that the A allele at rs363371 may protect against PD in Han Chinese males.

1. Introduction

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by static tremor, bradykinesia, rigidity, posture, gait dysfunction, and several nonmotor symptoms. The main pathological features of PD are aggregation of α-synuclein and selective loss of dopaminergic neurons in the substantia nigra pars compacta. Both motor and nonmotor PD symptoms are thought to be associated with protein and lipid oxidation mediated by the monoamine neurotransmitters dopamine and norepinephrine; this oxidation damages dopaminergic cells, as shown in animal studies of PD induced by 6-hydroxydopamine (6-OHDA) [1, 2]. Taken together, previous studies indicate that the storage and metabolism of monoamines, particularly dopamine, can influence levels of oxidative stress, which can in turn lead to PD.

Oxidative stress has been shown to arise from cytoplasmic dopamine rather than extracellular dopamine [3]. Homeostasis of cytoplasmic dopamine depends on normal functioning of both the dopamine transporter (DAT), which recycles dopamine from the extracellular medium into the cytoplasm, and the vesicular monoamine transporter 2 (VMAT2), which packages dopamine into vesicles and helps transport it to the extracellular medium [4]. VMAT2 dysfunction leads to excessive dopamine aggregation in the cytoplasm, where its metabolism generates reactive oxidative species such as ‘OH, O$_2^\cdot$ , H$_2$O$_2$, and neurotoxic quinones [2, 5, 6]. Thus VMAT2 dysfunction may contribute to PD via two pathways. One is that the reactive oxidative species inhibit mitochondrial respiration [7, 8], proteasome activity [9], and intracellular antioxidative defenses [10, 11], directly causing the degeneration of dopaminergic neurons in substantia nigra. The second pathway is through interaction between VMAT2 and α-synuclein. The α-synuclein protein is thought to contribute to PD pathogenesis by disturbing ion homeostasis, mitochondrial...
function, and proteostasis, as well as by inducing neuroinflammation [12]. VMAT2 hypomorphic mice overexpress α-synuclein in nigral dopamine neurons and show significantly more dopaminergic neurodegeneration than wild-type mice. This suggests that VMAT2 dysfunction leads to elevated intracellular dopamine levels, which may render dopaminergic neurons more susceptible to α-synuclein-mediated degeneration [13]. Thus, VMAT2 function may be essential to prevent endogenous dopamine from becoming neurotoxic [14].

It is not surprising, then, that two single-nucleotide polymorphisms (SNPs) in the promoter region of the VMAT2 gene, rs363371 and rs363324, have been associated with risk of PD in an Italian population: the A allele of rs363371 and the G allele of rs363324 were reported to decrease the risk of developing PD [15]. Studies of PD risk and other VMAT2 SNPs have come to different conclusions: two studies in Japan showed a negative association [16, 17], while four genome-wide association studies in Caucasians showed no association [18–21]. To verify whether rs363371 and rs363324 are associated with PD risk in other ethnic groups, the present study compared Han Chinese patients and controls. These findings complement the known association of SNPs in the dopamine transporter gene with risk of disease [22–24].

### 2. Subjects and Methods

**2.1. Subjects.** A total of 561 Han Chinese patients with sporadic PD and 491 unrelated, healthy Han Chinese control subjects were consecutively recruited from the movement disorder centers of West China Hospital, Sichuan University, located in southwest China, and of the First Affiliated Hospital of Sun Yat-sen University, located in southeast China. Clinical diagnosis of PD was established by two independent movement disorder specialists according to UK PD Society Brain Bank criteria for idiopathic PD [25]. Patients with at least one relative with PD were excluded. A neurologist confirmed that controls were free of any neurodegenerative disorders and family history of neurodegenerative disease for at least one generation. Written informed consent was obtained from all individuals involved in this research, and the study protocol was approved by the Ethics Committees at West China Hospital of Sichuan University and at the First Affiliated Hospital of Sun Yat-sen University.

**2.2. Genotyping.** Genomic DNA was obtained from peripheral leukocytes using classical phenol–chloroform extraction. All genotyping was performed by Shanghai Biowing Applied Biotechnology (Shanghai, China) using ligase detection reactions [26]. Target DNA sequences in the VMAT2 gene were amplified using a multiplex PCR method and the following sequences: rs262271 forward, 5'-AGTGAACC-AAGGCAGGAAC-3'; rs363371 reverse, 5'-CTCACATGG-CACAATGAATG-3'; rs363324 forward, 5'-CCCTGGAAC-TAATTCCTGTC-3'; rs363324 reverse, 5'-AATGCGCA-TGGACCATTC-3'. After amplification, 1 μL of proteinase K (20 mg/mL) was added and the reactions were heated at 70°C for 10 min and then quenched at 94°C for 15 min. The ligation reaction for each subject was carried out in a final volume of 20 μL containing 20 mM Tris–HCl (pH 7.6), 25 mM potassium acetate, 10 mM magnesium acetate, 10 mM DTT, 1 mM NAD, 0.1% Triton X-100, 10 μL of multiplex PCR product, 1 pmol of each discriminating oligo, 1 pmol of each common oligo, and 0.5 μL of 40 U/μL Tag DNA ligase (New England Biolabs, USA). The ligase detection reaction was then performed using 40 cycles of 94°C for 30 s and 63°C for 4 min. Fluorescent products were fractionated and analyzed using an ABI sequencer 377.

The technicians performing the genotyping were blinded to the case or control status of the samples. For quality control, 20% of the samples were randomly selected and processed independently by another researcher; all samples gave identical results in both researchers’ hands. We also selected 10 samples for each genotype of the two SNPs obtained by ligase detection reaction, and for more comprehensive characterization, we sequenced around the two SNPs using an ABI Prism 3730 automated sequencer, which showed 100% reproducibility.

**2.3. Statistical Analysis.** Age for different groups was reported as mean ± standard deviation (SD), while gender, allele, and genotype frequencies were determined by direct counting of alleles. Genotype distributions were tested for concordance with Hardy-Weinberg equilibrium (HWE). Differences in gender and age between PD and control groups were assessed for significance using, respectively, the chi-squared test and t-test. Logistic regression analysis was performed using PD as the dependent variable, while age and sex (Table 1). All statistical tests were carried out using SPSS 17.0 (IBM, Chicago, USA), using a significance threshold of P < 0.025 (corrected for multiple comparisons). Haplotype analysis was performed using SHEsis 4.0 online (http://analysis.bio-x.cn/myAnalysis.php). Genotype imputation was performed using IPUTE2 (http://mathgen.stats.ox.ac.uk/impute/impute_v2.html).

### 3. Results

**3.1. Basic Characteristics of PD and Control Subjects.** A total of 561 Han Chinese patients with PD (62.73 ± 11.74 years) and 491 healthy controls (61.8 ± 8.48 years) were included in the study. The PD and control groups were well matched by age and sex (Table 1). Among the PD patients, 167 had early-onset PD (EOPD), defined as disease with onset at 50 years;
Table 2: Distribution of genotypes and alleles at rs363371 and rs363324 among Han Chinese with Parkinson’s disease (PD) and healthy controls.

|                   | PD       | Controls | OR, 95% CI, P | OR, 95% CI, P* |
|-------------------|----------|----------|---------------|---------------|
| **rs363371**      |          |          |               |               |
| Genotype frequencies |         |          |               |               |
| AA                | 166 (29.6) | 148 (30.1) | —             | —             |
| AG                | 284 (50.6) | 255 (51.9) | 1.135, 0.794–1.621, 0.487 | 1.145, 0.798–1.643, 0.462 |
| GG                | 111 (19.8) | 88 (17.9) | 1.147, 0.827–1.590, 0.411 | 1.149, 0.826–1.598, 0.409 |
| Dominant model    |          |          |               |               |
| AA                | 166 (29.6) | 148 (30.1) | —             | —             |
| AG + GG           | 395 (70.4) | 343 (69.9) | 1.027, 0.788–1.338, 0.845 | 1.034, 0.791–1.352, 0.804 |
| Recessive model   |          |          |               |               |
| AA + AG           | 450 (80.2) | 403 (82.1) | —             | —             |
| GG                | 111 (19.8) | 88 (17.9) | 1.142, 0.838–1.557, 0.400 | 1.148, 0.839–1.570, 0.389 |
| Allele frequencies |          |          |               |               |
| A                 | 616 (54.9) | 551 (56.1) | —             | —             |
| G                 | 506 (45.1) | 431 (43.9) | 0.949, 0.828–1.088, 0.452 | 0.949, 0.827–1.090, 0.459 |

| **rs363324**      |          |          |               |               |
| Genotype frequencies |         |          |               |               |
| AA                | 21 (3.7)  | 19 (3.9)  | —             | —             |
| AG                | 206 (36.7) | 164 (33.6) | 0.994, 0.524–1.885, 0.985 | 0.937, 0.490–1.791, 0.844 |
| GG                | 334 (59.5) | 304 (62.4) | 0.875, 0.676–1.131, 0.308 | 0.865, 0.666–1.123, 0.275 |
| Dominant model    |          |          |               |               |
| AA                | 21 (3.7)  | 19 (3.9)  | —             | —             |
| AG + GG           | 540 (96.3) | 468 (96.1) | 1.044, 0.554–1.966, 0.894 | 0.989, 0.521–1.876, 0.972 |
| Recessive model   |          |          |               |               |
| AA + AG           | 227 (40.5) | 283 (74.1) | —             | —             |
| GG                | 334 (59.5) | 304 (25.9) | 0.886, 0.690–1.136, 0.340 | 0.872, 0.677–1.122, 0.287 |
| Allele frequencies |          |          |               |               |
| A                 | 248 (22.1) | 202 (20.7) | —             | —             |
| G                 | 874 (77.9) | 772 (79.3) | 1.084, 0.893–1.317, 0.413 | 1.105, 0.907–1.344, 0.321 |

PD: Parkinson's disease; CI: confidence interval; OR: odds ratio.

* P value for binary logistic regression after adjusting for age and gender.

3.2. Comparison of Genotype and Allele Frequencies between PD Patients and Controls. Genotype distributions at rs363371 were in HWE in patients (P = 0.597) and controls (P = 0.228); the same was true at rs363324 for patients (P = 0.116) and controls (P = 0.592). Genotype frequencies at both loci were similar between patients and controls (P > 0.05), and frequencies of the A allele were similar between both groups at both rs363371 (P > 0.05) and rs363324 (P > 0.321) (Table 2).

Next we performed subgroup analysis based on gender and genotype. Allele frequencies at rs363324 were similar between patients and controls in all subgroup analyses (Table 4). In contrast, we identified a significant difference in the frequency of the A allele at rs363371 between male PD patients and the male control group (OR 0.799, 95% CI 0.665 to 0.959, P = 0.016). This association remained significant after adjusting for age (OR 0.785, 95% CI 0.652 to 0.945, P = 0.011). No other subgroup analyses showed significant differences between patients and controls (Table 3).

3.3. Haplotype Analysis. The linkage disequilibrium D' value was 0.343 for rs363371 and rs363324, suggesting a strong recombination event. Haplotype analysis, in which haplotypes with frequencies <0.03 were excluded, identified the three haplotypes A-G, G-A, and G-G. None of these haplotypes showed a significant association with PD (Table 5).

3.4. Imputation. To provide independent verification of our findings, we used IMPUTE2 [27, 28] to perform direct imputation of the chromosomal region chr10:11898000–119041941, which includes the entire VMAT2 gene and an additional 5kb on either side of the gene. We included the option buffer(250) to force IMPUTE2 to use an internal buffer region of 250 kb on either side of the analysis window [27]. A dataset of 1000 genomes was downloaded from the IMPUTE2 website (http://mathgen.stats.ox.ac.uk/impute/impute_v2.html) [28] to serve as the imputation reference. The threshold for genotype calling was contained in the g-file...
Table 3: Distribution of genotype and alleles at rs363371 in Han Chinese PD patients and controls, stratified by gender.

|            | PD      | HC      | OR, 95% CI, P  | OR, 95% CI, P* |
|------------|---------|---------|---------------|---------------|
| **Males**  |         |         |               |               |
| Genotype frequency |          |         |               |               |
| AA         | 72 (23.8)| 87 (30.1)| —             | —             |
| AG         | 159 (52.6)| 152 (52.6)| 0.835, 0.571–1.221, 0.352| 0.807, 0.549–1.187, 0.276|
| GG         | 71 (23.3)| 50 (17.3)| 0.615, 0.383–0.989, 0.045| 0.594, 0.367–0.962, 0.034|
| Dominant model |          |         |               |               |
| AA         | 72 (23.8)| 87 (27.4)| —             | —             |
| AA + AG    | 230 (76.2)| 202 (72.6)| 0.767, 0.535–1.101, 0.767| 0.741, 0.514–1.070, 0.110|
| Recessive model |          |         |               |               |
| AA + AG    | 231 (76.5)| 239 (82.7)| —             | —             |
| GG         | 71 (23.5)| 50 (17.3)| 0.692, 0.462–1.037, 0.075| 0.684, 0.454–1.030, 0.069|
| Allele     |          |         |               |               |
| A          | 303 (50.2)| 326 (56.4)| 0.799, 0.665–0.959, 0.016| 0.785, 0.652–0.945, 0.011|
| G          | 301 (49.8)| 252 (43.6)| —             | —             |
| **Females**|         |         |               |               |
| Genotype frequency |          |         |               |               |
| AA         | 94 (36.3)| 61 (30.2)| —             | —             |
| AG         | 125 (48.3)| 103 (51)| 0.713, 0.472–1.079, 0.110| 0.691, 0.456–1.048, 0.082|
| GG         | 40 (15.4)| 38 (18.8)| 0.874, 0.637–1.199, 0.405| 0.871, 0.634–1.196, 0.393|
| Dominant model |          |         |               |               |
| AA         | 94 (36.3)| 61 (30.2)| —             | —             |
| AG + GG    | 165 (63.7)| 141 (69.8)| 1.252, 0.844–1.857, 0.264| 1.290, 0.897–1.856, 0.170|
| Recessive model |          |         |               |               |
| AA + AG    | 219 (84.6)| 164 (81.2)| —             | —             |
| GG         | 40 (15.4)| 38 (18.8)| 1.164, 0.871–1.555, 0.305| 1.185, 0.885–1.586, 0.256|
| Allele     |          |         |               |               |
| A          | 311 (60.4)| 225 (55.7)| —             | —             |
| G          | 205 (39.6)| 179 (44.3)| 0.844, 0.685–1.035, 0.108| 0.829, 0.673–1.022, 0.079|

PD: Parkinson's disease; HC: healthy controls; CI: confidence interval; OR: odds ratio.

*P value for binary logistic regression after adjusting for age.

(http://www.stats.ox.ac.uk/~marchini/software/gwas/file_format.html). For each SNP in each individual, the program uses the genotype with the maximum probability if that probability exceeds the threshold; otherwise, the genotype is treated as missing. An -Ne value of 20000 was used according to the manufacturer’s instructions to control effective population size in the population-genetic model used by the software. Nine SNPs were obtained after imputation: chr10:118987954:D, rs10886050, rs2532798, rs2532799, rs2619102, rs2619103, rs2803820, rs3026047, and rs4081624. After checking HWE and performing logistic regression, none of the nine SNPs was found to differ clearly between the case and control groups (see Supplementary Materials 1 and 2 available online at http://dx.doi.org/10.1155/2015/903164).

4. Discussion

Our study, inspired by the reported association between VMAT2 polymorphism at rs363371 and rs363324 and risk of PD in Italians [15], failed to reproduce these associations in a Han Chinese population. None of the three haplotypes identified in our population showed a significant association with disease. Even after imputation analysis, no obvious association was detected between VMAT2 and PD. On the other hand, subgroup analysis identified the A allele of rs363371 as protecting male Han Chinese from developing PD. These findings suggest that the effects of VMAT2 polymorphism on PD risk depend on ethnicity, highlighting the need for further study of these polymorphisms in other populations.

Our detection of an association between rs363371 and PD only in male Han Chinese contrasts with several lines of evidence implicating VMAT2 in PD pathology. A member of the SLC18A2 family of transporters, which are expressed primarily in the brain, VMAT2, is a 12-pass transmembrane protein [4] that packages dopamine and neurotoxins into secretion vesicles [29]. VMAT2 is expressed in the nigrostriatal area at 100-fold higher levels than in cerebellar or cerebral areas, and levels of nigrostriatal VMAT2 are lower in PD patients than in healthy controls [30, 31]. Studies in cell culture and animal models have provided additional evidence that VMAT2 dysfunction can lead to PD pathology. Cells
Table 4: Distribution of genotype and alleles at rs363324 among Han Chinese PD patients and controls, stratified by gender.

|                  | PD      | HC      | OR, 95% CI, P  | OR, 95% CI, P* |
|------------------|---------|---------|----------------|---------------|
| **Males**        |         |         |                |               |
| Genotype frequency |        |         |                |               |
| AA               | 12 (4)  | 12 (4.2)| —              | —             |
| AG               | 121 (40)| 98 (34.1)| 0.855, 0.395–1.983, 0.766 | 0.914, 0.403–2.072, 0.829 |
| GG               | 169 (56)| 177 (61.7)| 1.135, 0.513–2.510, 0.755 | 1.198, 0.535–2.682, 0.660 |
| Dominant model   |         |         |                |               |
| AA               | 12 (4)  | 12 (4.2)| —              | —             |
| AA + AG          | 290 (96)| 275 (95.8)| 1.031, 0.466–2.279, 0.940 | 1.078, 0.482–2.410, 0.855 |
| Recessive model  |         |         |                |               |
| AA + AG          | 133 (44)| 110 (38.3)| —              | —             |
| GG               | 169 (56)| 177 (61.7)| 1.266, 0.957–1.676, 0.099 | 1.300, 0.978–1.729, 0.071 |
| Allele           |         |         |                |               |
| A                | 145 (24)| 122 (21.3)| —              | —             |
| G                | 459 (76)| 452 (78.7)| 1.181, 0.918–1.519, 0.195 | 1.208, 0.936–1.560, 0.147 |
| **Females**      |         |         |                |               |
| Genotype frequency |        |         |                |               |
| AA               | 9 (3.5) | 7 (3.5) | —              | —             |
| AG               | 85 (32.8)| 66 (33) | 0.877, 0.310–2.480, 0.805 | 0.920, 0.323–2.619, 0.876 |
| GG               | 165 (63.7)| 127 (63.5)| 0.880, 0.316–2.447, 0.806 | 0.907, 0.324–2.539, 0.907 |
| Dominant model   |         |         |                |               |
| AA               | 9 (3.5) | 7 (3.5) | —              | —             |
| AG + GG          | 250 (96.5)| 193 (96.5)| 0.879, 0.316–2.444, 0.804 | 0.912, 0.326–2.554, 0.861 |
| Recessive model  |         |         |                |               |
| AA + AG          | 94 (36.3)| 73 (36.5)| —              | —             |
| GG               | 165 (63.7)| 127 (63.5)| 0.991, 0.769–1.278, 0.945 | 0.979, 0.758–1.246, 0.868 |
| Allele           |         |         |                |               |
| A                | 103 (19.9)| 80 (20) | —              | —             |
| G                | 415 (80.1)| 320 (80) | 0.981, 0.723–1.330, 0.901 | 0.975, 0.718–1.325, 0.975 |

PD: Parkinson's disease; HC: healthy controls; CI: confidence interval; OR: odds ratio.
*P value for binary logistic regression after adjusting for age.

Table 5: Haplotype frequencies in Han Chinese with PD and in healthy controls.

| SNP | Haplotype* | PD, n (%) | Controls, n (%) | X² | P   | OR [95% CI] |
|-----|------------|-----------|-----------------|----|-----|------------|
| 1, 2| A-G        | 619 (55.3)| 545 (56.1)      | 0.135 | 0.713 | 0.968 [0.818–1.151] |
|     | G-A        | 247 (22.1)| 201 (20.7)      | 0.567 | 0.448 | 1.084 [0.880–1.337] |
|     | G-G        | 254 (22.6)| 226 (23.2)      | 0.094 | 0.759 | 0.969 [0.790–1.188] |

SNP: single-nucleotide polymorphism.
*Only haplotypes with a frequency of P > 0.03 were considered in the analysis.
A, G indicate the allele at rs363371; A, G indicate the allele at rs363324.

Drug studies are also consistent with a link between VMAT2 and PD. Systemic administration of the VMAT2 inhibitor reserpine induces PD-like motor symptoms [36, 37] and nonmotor symptoms [38] in mice, as well as oxidative stress in the striatum [39, 40] and prefrontal cortex [39] of rat brain. Rotenone is widely used to model the death of dopamine neurons in Parkinson's disease both in vitro and in vivo, and the drug works via c-Jun N-terminal protein kinase (JNK) to inhibit VMAT2 [41]. Tetrabenazine (TBZ), a reversible inhibitor of VMAT2, preferentially depletes overexpressing α-synuclein show reduced VMAT2 activity, elevated cytosolic dopamine concentrations, and elevated levels of reactive oxidative species [32, 33]. A mouse line in which nondopaminergic striatal neurons lack VMAT2 but express dopamine transporter shows motor deficits, striatal neurodegeneration, and increased dopamine oxidation [34]. A transgenic mouse line expressing only 15% of the normal amount of VMAT2 closely mimics human PD characteristics, including deficits in l-DOPA-responsive motor activity and full-scale nonmotor symptoms [35].
striatal dopamine. Treating rats and mice with TBZ induces tremulous jaw movements as a model of parkinsonian tremor [42]. Treating dopaminergic cell with the VMAT2 inhibitor ketanserin exacerbates BH4-induced dopaminergic cell death and increases levels of lipid peroxidation and of protein-bound quinone, indicating greater oxidative stress [43]. Pramipexole, recommended for clinical use in early stages of PD, increases VMAT2 activity, increasing dopamine packaging and secretion in vesicles, reducing the cytosolic dopamine concentration, and thereby protecting dopaminergic neurons [44]. The antiparkinsonism drug apomorphine may work by a similar mechanism [45]. Together these studies suggest that VMAT2 is a quite promising therapeutic target against PD.

Given these numerous lines of evidence implicating VMAT2 dysfunction in PD pathology, it makes sense that we detected a protective effect of the A allele at rs363371 in Chinese males. We speculate that the protective A allele is associated with higher VMAT2 activity, and in fact this locus is in linkage disequilibrium with locus rs2619096, which doubles the activity of the VMAT2 promoter [46]. Surprisingly, despite the evidence for a link between VMAT2 dysfunction and PD, we failed to find any association between PD and the A allele at rs363371 in Chinese females, or between PD and the other alleles and genotypes that we tested. This discrepancy from the earlier study in Italians [15] may reflect ethnic differences. For example, the frequency of the A allele at rs363371 was 54.9%–56.1% in our subjects but only 19.2%–23.4% in Italian subjects [15].

Several studies have suggested that gender can modulate PD risk, with women showing lower incidence and prevalence of the disease [47]. Some studies suggest that estrogen and its signalling pathways account for some of these differences [48, 49]. The protective effects of estrogen appear to be related to inhibiting the function of the dopamine transporter [50, 51], preventing loss of VMAT2 [52], and other pathways [53]. Thus we could speculate that estrogen exerts neuroprotective effects on nigrostriatal neurons and that this estrogen effect is much stronger than the neuroprotective effect of VMAT2. As a result, the neuroprotective effects of VMAT2 may be more obvious in men, who have a relatively low concentration of estrogen. This model is consistent with our finding that the A allele of rs363371 appears to protect Han Chinese men from developing PD.

Our findings should be interpreted with caution because we did not take into account gene-gene or gene-environment interactions. We focused on only two SNPs in the VMAT2 gene, though we did expand this to nine in the imputation analysis, highlighting the need for more comprehensive studies of VMAT2 polymorphism involving next-generation sequencing. Our sample size is relatively small; nevertheless, power calculations that we performed prior to data collection based on the frequencies of G allele in Han Chinese (0.444; www.ncbi.nlm.nih.gov/projects/SNP) and the OR of 0.72 in the Italian study [15] suggested an anticipated power of 0.91 for rs363371 and 0.616 for 363324. These are reasonable power values to detect clinically important associations. All our PD patients came from southern China, so the discrepancy from the Italian study of the same polymorphisms [15] may simply reflect ethnic differences. The ethnic homogeneity in our study does have the advantage of reducing the risk of allelic heterogeneity and false positive associations, while increasing tagging efficiency [54].

In conclusion, our study suggests that VMAT2 polymorphism decreases the risk of developing PD in Han Chinese men. More studies are needed on the possible effects of VMAT2 polymorphisms on VMAT2 activity and risk of PD in larger populations and in other ethnic groups.

Conflict of Interests

The authors declare no conflict of interests.

Authors’ Contribution

Xinglong Yang, Pingrong Xu, Quanzhen Zhao, and Yanming Xu conceived and designed the trial. Ran An, Hua Jia, and Zhoulin Liu collected samples. Xinglong Yang and Quanzhen Zhao performed statistical analyses and drafted the paper. All authors reviewed the paper and approved the final version. Xinglong Yang, Pingrong Xu, and Quanzhen Zhao contributed equally to this work.

Acknowledgments

The authors thank all the patients and controls involved in this study. This research was supported by the National Natural Science Foundation of China (no. 81471300), the Sichuan Province Applied Basic Research Program (no. 2014JY0247), the Sichuan Key Project of Science and Technology (no. 2010SZ0086), and the Ministry of Science and Technology of China (2012AA02A514).

References

[1] M. Asanuma, I. Miyazaki, and N. Ogawa, "Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease," Neurotoxicology Research, vol. 5, no. 3, pp. 165–176, 2003.
[2] D. G. Graham, "Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones," Molecular Pharmacology, vol. 14, no. 4, pp. 633–643, 1978.
[3] E. V. Mosharov, K. E. Larsen, E. Kanter et al., "Interplay between cytosolic dopamine, calcium, and α-synuclein causes selective death of substantia nigra neurons," Neuron, vol. 62, no. 2, pp. 218–229, 2009.
[4] M. K. Schafer, E. Weihe, and L. E. Eiden, "Localization and expression of VMAT2 across mammalian species: a translational guide for its visualization and targeting in health and disease," in Advances in Pharmacology, vol. 68, chapter 15, pp. 319–334, 2013.
[5] T. J. Montine, M. J. Picklo, V. Amarnath, W. O. Whetsell Jr., and D. G. Graham, "Neurotoxicity of endogenous cysteinyldopachromes," Experimental Neurology, vol. 148, no. 1, pp. 26–33, 1997.
[6] T. G. Hastings, D. A. Lewis, and M. J. Zigmond, "Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections," Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 5, pp. 1956–1961, 1996.
[7] S. B. Berman and T. G. Hastings, "Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease," *Journal of Neurochemistry*, vol. 73, no. 3, pp. 1127–1137, 1999.

[8] M. E. Gluck, J. Ehrhart, E. Jayatilleke, and G. D. Zeevalk, "Inhibition of brain mitochondrial respiration by dopamine: involvement of H2O2 and hydroxyl radicals but not glutathione-protein-mixed disulfides," *Journal of Neurochemistry*, vol. 82, no. 1, pp. 66–74, 2002.

[9] K. S. Zafar, D. Siegel, and D. Ross, "A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4-dihydroxyphenylacetic acid in proteasomal inhibition," *Molecular Pharmacology*, vol. 70, no. 3, pp. 1079–1086, 2006.

[10] S.-K. Han and G. Cohen, "Inhibition of catase in mesencephalic cultures by L-DOPA and dopamine," *Neurochemistry International*, vol. 29, no. 6, pp. 645–649, 1996.

[11] J. H. Kang and K. S. Kim, "Enhanced oligomerization of the α-synuclein mutant by the Cu,Zn-superoxide dismutase and hydrogen peroxide system," *Molecules and Cells*, vol. 15, no. 1, pp. 87–93, 2003.

[12] B. Dehay, M. Bourdenx, P. Gorry et al., "Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations," *The Lancet Neurology*, 2015.

[13] A. Ulusoy, T. Björklund, K. Buck, and D. Kirik, "Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons," *Neurobiology of Disease*, vol. 47, no. 3, pp. 367–377, 2012.

[14] G. Eisenhofer, I. J. Kopin, and D. S. Goldstein, "Catecholamine metabolism: a contemporary view with implications for physiology and medicine," *Pharmacological Reviews*, vol. 56, no. 3, pp. 331–349, 2004.

[15] L. Brighina, C. Riva, F. Bertola et al., "Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson’s disease," *Neurobiology of Aging*, vol. 34, no. 6, pp. 1712.e9–1712.e13, 2013.

[16] S. Kariya, M. Hirano, N. Takahashi, Y. Furiya, and S. Ueno, "Lack of association between polymorphic microsatellites of the VMAT2 gene and Parkinson's disease in Japan," *Journal of the Neurological Sciences*, vol. 232, no. 1-2, pp. 91–94, 2005.

[17] I. Mizuta, W. Satake, Y. Nakabayashi et al., "Multiple candidate gene analysis identifies α-synuclein as a susceptibility gene for sporadic Parkinson’s disease," *Human Molecular Genetics*, vol. 15, no. 7, pp. 1151–1158, 2006.

[18] J. Simón-Sánchez, C. Schulte, J. M. Bras et al., "Genome-wide association study reveals genetic risk underlying Parkinson's disease," *Nature Genetics*, vol. 41, no. 12, pp. 1308–1312, 2009.

[19] N. Pankratz, J. B. Wilk, J. C. Latourelle et al., "Genomewide association study for susceptibility genes contributing to familial Parkinson disease," *Human Genetics*, vol. 124, no. 6, pp. 593–605, 2009.

[20] H.-C. Fung, S. Scholz, M. Matarin et al., "Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data," *The Lancet Neurology*, vol. 5, no. 11, pp. 911–916, 2006.

[21] D. M. Maraganore, M. de Andrade, T. C. Lesnick et al., "High-resolution whole-genome association study of Parkinson disease," *American Journal of Human Genetics*, vol. 77, no. 5, pp. 685–693, 2005.

[22] H. Morino, T. Karawari, Y. Izumi et al., "A single nucleotide polymorphism of dopamine transporter gene is associated with Parkinson's disease," *Annals of Neurology*, vol. 47, no. 4, pp. 528–531, 2000.

[23] M. Nishimura, R. Kaji, M. Ohta, I. Mizuta, and S. Kuno, "Association between dopamine transporter gene polymorphism and susceptibility to Parkinson’s disease in Japan," *Movement Disorders*, vol. 17, no. 4, pp. 831–832, 2002.

[24] B. R. Ritz, A. D. Manthripragada, S. Costello et al., "Dopamine transporter genetic variants and pesticides in Parkinson's disease," *Environmental Health Perspectives*, vol. 117, no. 6, pp. 964–969, 2009.

[25] D. B. Calne, B. J. Snow, and C. Lee, "Criteria for diagnosing Parkinson’s disease," *Annals of Neurology*, vol. 32, pp. S125–S127, 1992.

[26] G. Thomas, R. Sinville, S. Sutton et al., "Capillary and microelectrophoretic separations of ligase detection reaction products produced from low-abundant point mutations in genomic DNA," *Electrophoresis*, vol. 25, no. 10-11, pp. 1668–1677, 2004.

[27] J. Marchini, B. Howie, S. Myers, G. McVean, and P. Donnelly, "A new multipoint method for genome-wide association studies by imputation of genotypes," *Nature Genetics*, vol. 39, no. 7, pp. 906–913, 2007.

[28] J. Marchini, Homepage of IMPUTE2, https://mathgen.stats.ox.ac.uk/impute/impute_v2.html.

[29] F. S. Hall, K. Itokawa, A. Schmitt et al., "Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems," *Neuropharmacology*, vol. 76, pp. 146–155, 2014.

[30] J. Tong, I. Boileau, Y. Furukawa et al., "Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies," *Journal of Cerebral Blood Flow & Metabolism*, vol. 31, no. 10, pp. 2065–2075, 2011.

[31] K.-J. Lin, Y.-H. Weng, C.-J. Hsieh et al., "Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18-F-FP-(+)-DTBZ PET," *PLOS ONE*, vol. 8, no. 9, Article ID e75952, 2013.

[32] J. Lotharius and P. Brundin, "Impaired dopamine storage resulting from α-synuclein mutations may contribute to the pathogenesis of Parkinson's disease," *Human Molecular Genetics*, vol. 11, no. 20, pp. 2395–2407, 2002.

[33] E. V. Mosharov, R. G. W. Staal, I. Bové et al., "α-synuclein overexpression increases cytosolic catecholamine concentration," *Journal of Neuroscience*, vol. 26, no. 36, pp. 9304–9311, 2006.

[34] L. Chen, Y. Ding, B. Cagniard et al., "Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice," *The Journal of Neuroscience*, vol. 28, no. 2, pp. 425–433, 2008.

[35] G. W. Miller, T. N. Taylor, and W. M. Caudle, "VMAT2-deficient mice display nigral and extranigral pathology and motor and nonmotor symptoms of Parkinson’s disease," *Parkinson’s Disease*, vol. 2011, Article ID 124165, 9 pages, 2011.

[36] F. C. Colpaert, "Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat," *Neuropharmacology*, vol. 26, no. 9, pp. 1431–1440, 1987.

[37] R. H. Silva, V. C. Abilio, D. Torres-Leite et al., "Concomitant development of oral dyskinesia and memory deficits in reserpine-treated male and female mice," *Behavioural Brain Research*, vol. 132, no. 2, pp. 171–177, 2002.

[38] L. L. Skalisz, V. Beijamini, S. L. Joca, M. A. B. F. Vital, C. Da Cunha, and R. Andreatini, "Evaluation of the face validity of reserpine administration as an animal model of depression: Parkinson's disease association," *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, vol. 26, no. 5, pp. 879–883, 2002.
[39] A. Bilska, M. Dubiel, M. Sokołowska-Jezewicz, E. Lorenc-Koci, and L. Włodek, “Alpha-lipoic acid differently affects the reserpine-induced oxidative stress in the striatum and prefrontal cortex of rat brain,” *Neuroscience*, vol. 146, no. 4, pp. 1758–1771, 2007.

[40] V. S. Fernandes, J. R. Santos, A. H. Leão et al., “Repeated treatment with a low dose of reserpine as a progressive model of Parkinson’s disease,” *Behavioural Brain Research*, vol. 231, no. 1, pp. 154–163, 2012.

[41] W.-S. Choi, H.-W. Kim, and Z. Xia, “NK inhibition of VMAT2 contributes to rotenone-induced oxidative stress and dopamine neuron death,” *Toxicology*, vol. 328, pp. 75–81, 2015.

[42] S. J. Podurgiel, E. J. Nunes, S. E. Yohn et al., “The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: implications for pharmacological models of parkinsonian tremor,” *Neurochemistry International*, vol. 250, pp. 507–519, 2013.

[43] H. J. Choi, S. Y. Lee, Y. Cho, and O. Hwang, “Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson’s disease,” *Neurochemistry International*, vol. 46, no. 4, pp. 329–335, 2005.

[44] J. G. Truong, K. S. Rau, G. R. Hanson, and A. E. Fleckenstein, “Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson’s neurodegeneration,” *European Journal of Pharmacology*, vol. 474, no. 2-3, pp. 223–226, 2003.

[45] J. G. Truong, G. R. Hanson, and A. E. Fleckenstein, “Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration;” *European Journal of Pharmacology*, vol. 492, no. 2-3, pp. 143–147, 2004.

[46] Z. Lin, D. Walther, X.-Y. Yu, S. Li, T. Drgon, and G. R. Uhl, “SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism,” *Human Molecular Genetics*, vol. 14, no. 10, pp. 1393–1404, 2005.

[47] G. F. Wooten, L. J. Currie, V. E. Bovbjerg, J. K. Lee, and J. Patric, “Are men at greater risk for Parkinson’s disease than women?” *Journal of Neurology, Neurosurgery and Psychiatry*, vol. 75, no. 4, pp. 637–639, 2004.

[48] S. Petrovska, B. Dejanova, and V. Jurisic, “Estrogens: mechanisms of neuroprotective effects,” *Journal of Physiology and Biochemistry*, vol. 68, no. 3, pp. 455–460, 2012.

[49] S. Al Sweidi, M. G. Sánchez, M. Bourque, M. Morissette, D. Dluzen, and T. Di Paolo, “Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson’s disease,” *Journal of Neuroendocrinology*, vol. 24, no. 1, pp. 48–61, 2012.

[50] K. A. Disshon and D. E. Dluzen, “Use of in vitro superfusion to assess the dynamics of striatal dopamine clearance: influence of estrogen,” *Brain Research*, vol. 842, no. 2, pp. 399–407, 1999.

[51] K. A. Disshon, J. W. Boja, and D. E. Dluzen, “Inhibition of striatal dopamine transporter activity by 17β-estradiol,” *European Journal of Pharmacology*, vol. 345, no. 2, pp. 207–211, 1998.

[52] S. Jourdain, M. Morissette, N. Morin, and T. Di Paolo, “Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantianigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice,” *Journal of Neuroendocrinology*, vol. 17, no. 8, pp. 509–517, 2005.

[53] K. M. Smith and N. Dahodwala, “Sex differences in Parkinson’s disease and other movement disorders,” *Experimental Neurology*, vol. 259, pp. 44–56, 2014.

[54] A. F. Wright, A. D. Carothers, and M. Pirastu, “Population choice in mapping genes for complex diseases,” *Nature Genetics*, vol. 23, no. 4, pp. 397–404, 1999.